CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 136 enrolled
Drug / intervention
Naloxegol 25 MG +1 moredrug
Likely dose
Naloxegol 25 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03235739
NCT03235739Phase 4Completed
CompareCT.gov

Ancillary Effects of Oral Naloxegol (Movantik)

The Cleveland Clinic·interventional·Posted Aug 1, 2017·Updated Sep 5, 2023

In Brief

A Phase 4 clinical trial evaluating Naloxegol 25 MG and Placebo for Pain, Postoperative. Completed, enrolled 136 participants across 1 site.

Detailed Summary

The purpose of this study is to find out whether oral Naloxegol can reduce the side effects of opioid painkillers following surgery. This study aims to explore whether Naloxegol can similarly reduce opioid-induced side effects in post-surgical patients. About 130 surgery patients will participate in this study which is being conducted at Cleveland Clinic Main Campus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 1, 2017
Enrollment StartOct 1, 2017
Primary CompletionMay 31, 2021
Study CompletionMay 23, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.9 years ago

Interventions

Naloxegol 25 MGdrug

Oral Naloxegol 25 MG

Placebodrug

matching oral placebo